Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case reportReportar como inadecuado




Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 10:696

Clinical oncology

Abstract

BackgroundStereotactic body radiation therapy SBRT applied by helical tomotherapy HT is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer NSCLC is not reported previously.

Case PresentationA 77-year-old man with stage III NSCLC, received erlotinib 150 mg-day, combined with image-guided SBRT via HT. A total tumor dose of 54 Gy-9 fractions was delivered to the tumor bed. The tumor responded dramatically and the combined regimen was well tolerated. After concurrent erlotinib-SBRT, erlotinib was continued as maintenance therapy. The patient developed dyspnea three months after the combined therapy and radiation pneumonitis with interstitial lung disease was suspected.

ConclusionsCombination SBRT, HT, and erlotinib therapy provided effective anti-tumor results. Nonetheless, the potential risks of enhanced adverse effects between radiation and erlotinib should be monitored closely, especially when SBRT is part of the regimen.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-10-696 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor:

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados